ALNY News and Press, Alnylam Pharmaceuticals Inc. From 01/02/24

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:45 am PT (12:45 pm ...

2023-12-22 12:00:02 ET William Blair analyst issues OUTPERFORM recommendation for ALNY on December 22, 2023 12:04PM ET. The previous analyst recommendation was Outperform. ALNY was trading at $190.91 at issue of the analyst recommendation. The overall analyst consensus :...

2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...

2023-12-18 09:00:00 ET Summary Alnylam plans to significantly expand its clinical pipeline by the end of 2025, with over 15 new candidates entering the clinic. The company is targeting obesity and type 2 diabetes with liver, adipose, and muscle-directed candidates. Alnylam's n...

– Company Anticipates Investigational New Drug (IND) Applications for Nine or More Programs with Targets Expressed in the Liver, Central Nervous System, Adipose Tissue, and Muscle by End of 2025 – – Positive Initial Phase 1 Results with ALN-TTRsc04 Demonstrate Rapid K...

2023-12-04 09:50:28 ET More on SPDR S&P 500 ETF Trust: Bears Refuse To Acknowledge New All-Time Highs In 2024 SPY Is A Buy According To The 200-Day Simple Moving Average When Do You Take Profits? Top 10 trades for 2024 - BofA S&P 500 hits new ...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-12-01 09:00:08 ET Summary Shares of Arrowhead Pharmaceuticals dropped this week after the company reported fiscal Q3 2023 results. Balance sheet concerns are weighing on the stock, and this is an urgent issue the company needs to address, and it has several options at its dis...

– Recognition Marks Alnylam’s Ninth Year in a Row on this Prestigious List, and the Third Consecutive Year Ranking #1 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’...

2023-11-21 00:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...